Use of Patient and Disease Characteristics as Predictive Indicators of Rituximab Infusion-Related Reactions in Adult Malignant Hematology Patients at an Academic Medical Center-Reference-Cited by-同舟云学术

Use of Patient and Disease Characteristics as Predictive Indicators of Rituximab Infusion-Related Reactions in Adult Malignant Hematology Patients at an Academic Medical Center

Published:2019-11 Issue:11 Volume:19 Page:723-728
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Kowalski Kaitlyn E.,Adams C. Brooke,Voils Stacy A.,Wheeler Sarah E.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference12 articles.

1. Rituxan (rituximab) [package insert],2018

2. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8);Winkler;Blood,1999

3. World Allergy Organization ad hoc Committee on Epinephrine in Anaphylaxis. Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization;Kemp;Allergy,2008

4. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity;Byrd;J Clin Oncol,2001

5. Tolerability and safety of rituximab (MabThera);Kimby;Cancer Treat Rev,2005

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients with infusion-related reactions on fixed-dose rituximab treatment have higher body surface area than those without infusion-related reactions in adults with frequently relapsing minimal change nephrotic syndrome: a retrospective study;Journal of Pharmaceutical Health Care and Sciences;2024-02-22

2. Analysis of Risk Factors for Infusion-Related Reactions Following Rituximab Administration in Patients with Desensitization before Renal Transplantation;Biological and Pharmaceutical Bulletin;2023-09-01

3. Exploring Predictive Risk Factors of Infusion Reactions with First Pertuzumab Administration in HER2-positive Breast Cancer Patients: A Single Institution Experience;JMA Journal;2023

4. Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma;Advances in Hematology;2022-02-11

5. Impact of Split Dosing the First Rituximab Infusion in Patients with High Lymphocyte Count;Current Oncology;2021-10-13